Funding Round
<cite index="2-2">Neko Health, founded by Spotify's Daniel Ek and Hjalmar Nilsonne, announced the completion of its $700 million Series C funding round on July 15, 2026.</cite> <cite index="4-5">The pre-empted round values the Swedish-born company at nearly $7 billion — a roughly fourfold increase from its $1.7 billion Series B valuation in January 2025.</cite> <cite index="7-1">The raise puts Neko's total funding to date at over $1 billion.</cite>
<cite index="2-3,2-4">The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst, and Lakestar, alongside new backers including Liberty City Ventures, Positive Sum, and BDT & MSD.</cite> <cite index="2-5,2-6">As part of the round, David Ofer of O.G. Venture Partners will join the Board of Directors, subject to regulatory approval.</cite> The round also attracted a broad group of individual investors, <cite index="18-7">including Ari Emanuel, Claudia Schiffer and Sir Matthew Vaughn, Danny Meyer, Jimmy Iovine, Maria Sharapova, Mark Zuckerberg and Priscilla Chan, Thierry Henry, Tim Ferriss, and will.i.am.</cite>
Product and Technology
<cite index="7-12">Co-founded in 2018 by Hjalmar Nilsonne and Daniel Ek, the health technology startup's non-invasive Neko Health Scan uses 70 scanners and a combination of technologies, including thermal imaging and 2D/3D photography, to map approximately 50 million health data points in a user's body.</cite> <cite index="5-7">The scan is a 60-minute, comprehensive, non-invasive, and radiation-free health assessment, priced at £299 in the UK and 2,750 SEK in Sweden.</cite> <cite index="13-7">Using proprietary sensors alongside blood analysis, the scan assesses skin health — including moles and marks — biomarkers to identify pre-diabetes risk, blood abnormalities, and risk factors linked to metabolic syndrome, stroke, and heart attack.</cite>
<cite index="4-7">Neko operates a vertically integrated business model, engineering its own proprietary imaging hardware, clinical software, and clinic footprint in-house.</cite> <cite index="9-17">In June 2026, the company added wearable integration and body composition analysis and opened a new Stockholm clinic featuring next-generation devices called Derma-2, Echo-2, and Spectrum-2.</cite> <cite index="5-19">The company attributes this pace of continuous innovation to its ownership of every part of its technology stack in-house.</cite> <cite index="13-5">Neko Health does not use large medical imaging machines like MRIs for its scans, unlike competitors Prenuvo and Ezra.</cite>
US Expansion and Leadership
<cite index="2-18">With its first US clinics opening in New York and other cities in 2026, Neko will use the funding to scale its preventive healthcare platform.</cite> <cite index="8-6">To support this effort, the company hired Dr. Sunita Mishra as chief medical officer (CMO) in March 2026; she previously served as CMO at Amazon Health.</cite> <cite index="17-22,17-23">The scan costs £299 in the UK and 2,750 SEK in Sweden; Neko Health has not announced US pricing but indicated to MedCity News that it will be "commensurate with the UK."</cite>
Clinical Outcomes and Market Traction
<cite index="1-9">The company says more than 100,000 people have already had scans, and more than 350,000 people have either registered for the waitlist or set an appointment.</cite> <cite index="11-15">At the end of their first appointment, 75% of members book and prepay for their next scan.</cite> <cite index="5-10,5-11">Neko Health reports that three in four returning members with previously identified severe or life-threatening conditions were in good health or had their conditions under control, and that five of seven key biomarkers showed statistically significant improvement between a member's first and second scan.</cite>
Competitive Landscape
<cite index="13-11,13-12">Elective, direct-to-consumer full-body scanning is a growing market, fueled by advances in artificial intelligence; it was valued at $29.7 billion in 2025 and is projected to reach $47.2 billion by 2033, according to data from SNS Insider.</cite> <cite index="9-22,9-23">In the US, Prenuvo — which offers whole-body MRI scans — has raised $192 million and generates approximately $250 million in annual revenue, while Function Health, a blood-biomarker platform, reached a $2.5 billion valuation in November 2025 after raising $298 million.</cite> <cite index="6-12">Some physicians have questioned whether whole-body scans detect enough disease to justify the cost and the risk of false positives.</cite>